论文信息 - Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib - 字舞流文

Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib

C. Clouser | Ronald J. Hause | R. Ponce | C. Krejsa | Jon C Jones | Timothy G. Johnstone | Michael O. Ports | J. Qin | S. Ragan | Alex Baturevych | R. Salmon